Skip to main content

GH

Stock
Health Care
Diagnostics & Research

Performance overview

GH Price
Price Chart

Forward-looking statistics

Beta
1.77
Risk
71.36%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

we believe conquering cancer is a big data problem. that’s why we built the world’s leading comprehensive liquid biopsy. this non-invasive tool for accessing and sequencing tumor dna is used by thousands of oncologists to help tens of thousands of advanced cancer patients. we believe the boom in cancer data acquisition we helped launch will drive important discoveries and new products. we’re working on some exciting ones, including in early detection, where the impact on patients can be profound. we’ve raised more than $500 million from investors including sequoia capital, khosla ventures, orbimed, and softbank.

Company info

SectorHealth Care
IndustryDiagnostics & Research
Employees2K
Market cap$3.5B

Fundamentals

Enterprise value$7.1B
Revenue$774.0M
Revenue per employee
Profit margin-53.82%
Debt to equity-5.21

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$3.39
Dividend per share
Revenue per share$6.28
Avg trading volume (30 day)$94M
Avg trading volume (10 day)$88M
Put-call ratio

Macro factor sensitivity

Growth-2.7
Credit+7.5
Liquidity-0.6
Inflation-6.5
Commodities-1.4
Interest Rates-2.3

Valuation

Dividend yield0.00%
PEG Ratio-18.63
Price to sales8.08
P/E Ratio-18.63
Enterprise Value to Revenue9.12
Price to book-24.94

Upcoming events

Next earnings dayAugust 6, 2025
Next dividend day
Ex. dividend day

News

Why Super Group (SGHC) Limited (SGHC) Dipped More Than Broader Market Today

In the latest trading session, Super Group (SGHC) Limited (SGHC) closed at $11.65, marking a -1.02% move from the previous day.

Zacks Investment Research (July 18, 2025)
Wall Street Analysts Believe GH Research (GHRS) Could Rally 107.25%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 107.3% in GH Research (GHRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research (July 16, 2025)
Super Group (SGHC) Limited (SGHC) Stock Declines While Market Improves: Some Information for Investors

Super Group (SGHC) Limited (SGHC) closed at $11.79 in the latest trading session, marking a -1.67% move from the prior day.

Zacks Investment Research (July 10, 2025)
TEM vs. GH: Which AI in Precision Oncology Stock Has More Upside Now?

GH gains ground with stronger guidance, improving margin and Reveal's breakout as TEM scales fast but stays unprofitable.

Zacks Investment Research (June 23, 2025)
Why Is Cancer Diagnostic Guardant Health Stock Trading Higher On Tuesday?

Guardant Health, Inc. GH stock is trading higher on Tuesday after the U.S. Food and Drug Administration (FDA) granted Breakthrough Device designation to the company's Shield multi-cancer detection (MCD) test.

Benzinga (June 3, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free